Intended for healthcare professionals

Letters New UK drug strategy

Is the UK’s 2017 drug strategy fit for purpose?

BMJ 2017; 358 doi: (Published 29 September 2017) Cite this as: BMJ 2017;358:j4405
  1. Chris Ford, clinical director1,
  2. David Nutt, chair2,
  3. Niamh Eastwood, executive director3,
  4. Deborah Gold, chief executive4,
  5. John Jolly, chief executive5,
  6. Fionnuala Murphy, head of advocacy6,
  7. Kate Halliday, executive director7,
  8. Jamie Bridge, senior policy and operations manager8
  1. 1International Doctors for Healthier Drug Policies, London NW1 0JH, UK
  2. 2Drug Science, London SW8 1GB, UK
  3. 3Release, London EC1V 2NJ, UK
  4. 4National AIDS Trust, London EC1V 9FR, UK
  5. 5Blenheim CDP, London SW8 2JU, UK
  6. 6Harm Reduction International, London SE1 6LN, UK
  7. 7Substance Misuse Management Good Practice (SMMGP), Box 200, London SW19 1LJ, UK
  8. 8International Drug Policy Consortium, London EC1V 2NJ, UK

The UK government has published its 2017 drug strategy,12 and we are greatly concerned at the lack of focus on harm reduction—an evidence based response that protects people and saves lives—at a time when drug related deaths are the highest on record. The government acknowledges in the strategy that the rise in drug related deaths is “dramatic and …

View Full Text

Log in

Log in through your institution


* For online subscription